— Know what they know.
Not Investment Advice

REPH NASDAQ

Recro Pharma, Inc.
1W: +7.2% 1M: +25.1% 3M: +26.7% 1Y: -43.4% 3Y: -78.2% 5Y: -73.8%
$2.09
Last traded 2022-03-21 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $177.4M mcap · 70M float · 0.184% daily turnover

Balance Sheet Trends

Total Assets
$153M -2.5% ▼
5Y CAGR: -0.3%
Total Liabilities
$95M -2.8% ▼
5Y CAGR: -11.5%
Shareholders Equity
$59M -2.0% ▼
Cash & Investments
$8M -46.0% ▼
5Y CAGR: -26.8%
Total Debt
$42M +217.3% ▲
5Y CAGR: -8.1%
Net Debt
$34M +2032.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$19M$24M$25M$15M$8M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$19M$24M$25M$15M$8M
Net Receivables$14M$9M$12M$16M$17M
Inventory$15M$12M$9M$10M$10M
Other Current Assets$12M$10M$11M$14M$19M
Total Current Assets$60M$54M$58M$56M$53M
Property, Plant & Equip.$43M$44M$58M$50M$55M
Goodwill & Intangibles$8M$5M$45M$44M$43M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$486K$246K$7M$2M
Total Non-Current Assets$50M$49M$103M$102M$100M
Total Assets$110M$103M$160M$157M$153M
— Liabilities —
Accounts Payable$989K$2M$2M$1M$1M
Short-Term Debt$148K$1M$3M$9M$38M
Deferred Revenue$337K$1M$2M$0$0
Other Current Liabilities$5M$5M$13M$13M$11M
Total Current Liabilities$6M$8M$18M$23M$50M
Long-Term Debt$111M$0$5M$5M$4M
Other Non-Current Liab.$0$110M$96M$70M$41M
Total Non-Current Liabilities$111M$110M$101M$75M$45M
Total Liabilities$117M$118M$118M$98M$95M
— Equity —
Common Stock$233K$286K$467K$846K$1M
Retained Earnings-$207M-$234M-$246M-$266M-$279M
Accumulated OCI-$24M$0$0$0$0
Total Stockholders Equity-$7M-$14M$42M$60M$59M
Total Liabilities & Equity$110M$103M$160M$157M$153M
— Key Metrics —
Total Debt$111M$110M$104M$13M$42M
Net Debt$92M$86M$78M-$2M$34M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms